echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The new crown DNA vaccine is approved to deal with the Delta strain and can be used to vaccinate adolescents

    The new crown DNA vaccine is approved to deal with the Delta strain and can be used to vaccinate adolescents

    • Last Update: 2021-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On August 20, the new crown DNA vaccine ZyCoV-D was approved for emergency use (EUA) in India.


    ZyCov-D has shown excellent safety and effectiveness against DNA variants in Phase III clinical trials.


    Following the success of the mRNA vaccine at the end of last year, the DNA vaccine was finally successful


    Phase III clinical data show that DNA vaccines are effective against Delta variants

    Phase III clinical data show that DNA vaccines are effective against Delta variants

    The new crown DNA vaccine ZyCov-D has conducted the country's largest Phase III clinical trial so far in India, involving more than 50 bases and a total of 28,000 subjects


    The Phase III clinical trial in India also proved that the new crown DNA vaccine is very safe and tolerable


    The principle of DNA vaccines is to design and synthesize DNA plasmids carrying antigen sequences according to the Central dogma of molecular biology, which is transcribed into mRNA in human cells and then translated into proteins to activate the human immune system


    There are more than ten new coronavirus DNA vaccines in the world.


    There are more than ten new coronavirus DNA vaccines in the world.


    In the face of many technological pioneers, why can India achieve a turnaround? The main reason is that the speed of the Phase III clinical trial of the new crown vaccine mainly depends on the incidence of the clinical research country.


    It is worth noting that, according to ZyCov-D’s published technical information, it is highly consistent with the sequence design of pGX9501/INO-4800.


    The development of DNA vaccine technology and China's accumulation in this field

    The development of DNA vaccine technology and China's accumulation in this field

    Both DNA vaccine technology and mRNA vaccine technology were born in the early 1990s


    In terms of the transformation of scientific achievements, Professor DavidB.


    In addition to Ai Di Weixin Biopharmaceuticals, many domestic companies and research institutes have joined the research and development of various DNA vaccines


    DNA vaccine and mRNA vaccine, the dual future of nucleic acid vaccine

    DNA vaccine and mRNA vaccine, the dual future of nucleic acid vaccine

    DNA vaccines and mRNA vaccines are called "third-generation" nucleic acid vaccine technologies


    At the end of 2020, two mRNA vaccines of BioNTech and Moderna were approved for the prevention of new coronary pneumonia.


    With the addition of DNA vaccines, the era of nucleic acid vaccines has come


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.